-
Infinity Pharmaceuticals Notches Upgrade Ahead Of Cancer Conference Presentation
Thursday, October 12, 2017 - 12:27pm | 601Read More...Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares are soaring Thursday after an upgrade by Wells Fargo. The biopharma company's IPI-549 monotherapy data was selected for a "late-breaker" oral presentation at the Society of Immunotherapy of Cancer's annual meeting in November,...
-
Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors
Thursday, January 19, 2017 - 1:29pm | 1018Read More...Verastem Inc (NASDAQ: VSTM) is a biopharmaceutical company that focuses on discovering and developing therapies for the treatment of patients with cancer. Verastem acquired a license agreement from Infinity Pharmaceuticals granting Verastem exclusive worldwide rights to develop and...
-
Earnings Expectations for the Week of March 12 (URBN, ROST)
Sunday, March 11, 2012 - 11:04am | 1206Read More...Things will quiet on the earnings front this week. Perhaps the two most prominent quarterly reports will come from retailers and S&P 500 components Urban Outfitters (NASDAQ: URBN) and Ross Stores (NASDAQ: ROST). Analysts on average expect both companies to post year-over-year revenue growth of...
-
Piper Jaffray Maintains Overweight on Infinity Pharmaceuticals
Tuesday, June 7, 2011 - 7:55am | 133Read More...Piper Jaffray is out with its report today on Infinity Pharmaceuticals (NASDAQ: INFI), maintaining Overweight. In a note to clients, Piper Jaffray writes, "Infinity presented 2 posters on intravenous Heat Shock Protein-90 inhibitor retaspimycin including Phase Ib data in combination with Taxotere...
-
Piper Jaffray Reiterates Overweight Rating, $9 PT on Infinity Pharmaceuticals
Monday, June 6, 2011 - 7:28am | 116Read More...Piper Jaffray is reiterating its Overweight rating and $9 price target on shares of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) “based on a projected enterprise value of $174 million + YE11E cash of $63 million.” “On Saturday, Infinity presented 2 posters on oral Hedgehog inhibitor IPI-926 at...
-
Jefferies & Company Reports on Infinity Pharmaceuticals (INFI)
Wednesday, May 11, 2011 - 8:05am | 127Read More...In a report released earlier today, Jefferies & Company commented on Infinity Pharmaceuticals (NASDAQ: INFI). In the report, Jefferies was positive. Jefferies writes, “[INFI] reported a narrower 1Q11 loss on higher revenues; cash of $91M at end-1Q11, $200M-$205M committed R&D funding in...
-
UPDATE: Piper Jaffray Upgrades Infinity Pharmaceuticals to Overweight (INFI)
Monday, May 9, 2011 - 9:13am | 151Read More...Piper Jaffray is out with its report today on Infinity Pharmaceuticals (NASDAQ: INFI), upgrading INFI from Neutral to Overweight. In a note to clients, Piper Jaffray writes, "We look for shares of INFI to trade higher into ASCO next month, where Infinity will report Phase Ib proof-of-concept...
-
Piper Jaffray Raises INFI Target From $6 To $9, Upgrades Shares To OW
Monday, May 9, 2011 - 7:22am | 34Read More...Piper Jaffray is upgrading shares of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) from Neutral to Overweight while raising its PT from $6 to $9. Infinity Pharmaceuticals closed Friday at $5.79.
-
Piper Jaffray Reports Infinity Initiated Studies In Pancreatic Cancer And Chondrosarcoma
Tuesday, April 5, 2011 - 7:27am | 89Read More...According to Piper Jaffray, Infinity Pharmaceuticals (NASDAQ: INFI) has initiated Phase II studies in pancreatic cancer and chondrosarcoma. Piper Jaffray reported that it is attending the American Association for Cancer Research (AACR) meeting in Orlando. “We are sensing increased excitement...
-
INFI Shows Strong Cash Position After Weak 2Q
Thursday, August 5, 2010 - 10:21am | 85Read More...Infinity Pharmaceuticals (NASDAQ: INFI) has emerged from its 2Q in a strong cash position ($120M) which is expected to be sufficient through 2012, according to Jefferies. Jefferies states that INFI's cancer/autoimmune disease programs are facing challenges, but the cash backing should provide...
